Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | PYGL | P06737 | 1/20 | 0.35 |
| ▸ | PYGM | P11217 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.33 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1853358 | 0.81 | ALDH1A1 (0.46) | LRRK2GRM4CLK4GRM5PYGL | |
| SCHEMBL22637041 | 0.81 | GRM4 (0.38) | LRRK2GRM4CLK4GRM5PYGL | |
| SCHEMBL19631996 | 0.79 | KDM4E (0.49) | LRRK2GRM4CLK4GRM5PYGL | |
| SCHEMBL3511788 | 0.76 | TTR (0.45) | TTRALB | |
| SCHEMBL5936390 | 0.76 | KDM4C (0.55) | LRRK2GRM4GRM5PYGLPYGM | |
| Water SCHEMBL347466 | 0.76 | KDM4C (0.55) | LRRK2GRM4GRM5PYGLPYGM | |
| SCHEMBL17495430 | 0.74 | GRM4 (0.48) | LRRK2GRM4CLK4GRM5PYGL | |
| SCHEMBL7718659 | 0.74 | MYC (0.47) | LRRK2GRM4GRM5PYGLPYGM | |
| SCHEMBL9324648 | 0.74 | RAB9A (0.42) | LRRK2GRM4GRM5PYGLPYGM | |
| SCHEMBL17546406 | 0.74 | LRRK2 (0.48) | LRRK2GRM4GRM5PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
| WO-2020227101-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
| US-8563732-B2 | Oxyimino compounds and the use thereof | SHIONOGI & CO., LTD. (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8299267-B2 | (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating | COMENTIS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC | 2010-11-11 | — | — | US | disclosed |
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2010-09-23 | — | — | US | disclosed |
| EP-2205596-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2010-07-14 | — | — | EP | disclosed |
| EP-2178837-A2 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | COMENTIS, INC. (US) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009042694-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | COMENTIS, INC. (US) | 2009-04-02 | — | — | WO | disclosed |
| WO-2009015369-A2 | COMPOUNDS WHICH INHIBIT BETA-SECRETASE ACTIVITY AND METHODS OF USE THEREOF | COMENTIS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286145-A1 | ISOPHTHALAMIDE DERIVATIVES INHIBITING BETA-SECRETASE ACTIVITY | BACE1, BACE2, APP | LRRK2 728/4885GRM4 1765/4885CLK4 4582/4885 |
| US-20100286170-A1 | (3-HYDROXY-4-AMINO-BUTAN-2-YL) -3- (2-THIAZOL-2-YL-PYRROLIDINE-1-CARBONYL) BENZAMIDE DERIVATIVES AND RELATED COMPOUNDS AS BETA-SECRETASE INHIBITORS FOR TREATING | BACE1, BACE2, PSEN1 | LRRK2 186/4885GRM4 1490/4885CLK4 3723/4885 |
| US-20100240703-A1 | OXYIMINO COMPOUNDS AND THE USE THEREOF | CACNA1A, CACNA1S, OPRM1 | LRRK2 4100/4885GRM4 1062/4885CLK4 2478/4885 |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | LRRK2 658/4885GRM4 518/4885CLK4 1821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.